Related Experiment Video

Updated: Aug 30, 2026

Assessment of Sarcoplasmic Reticulum Calcium Reserve and Intracellular Diastolic Calcium Removal in Isolated Ventricular Cardiomyocytes
11:00

Assessment of Sarcoplasmic Reticulum Calcium Reserve and Intracellular Diastolic Calcium Removal in Isolated Ventricular Cardiomyocytes

Published on: September 18, 2017

Long-term glucose insulin potassium infusion improves systolic and diastolic function in patients with chronic

Sait Alan1, Mehmet S Ulgen, Ibrahim Dedeoglu

  • 1Department of Cardiology, Dicle University School of Medicine, Diyarbakir, Turkey. saitalan@dicle.edu.tr

Swiss Medical Weekly
|October 17, 2003
PubMed

Insights

Glucose-insulin-potassium (GIK) infusion significantly improved systolic and diastolic function in patients with stable coronary disease and reduced ejection fraction. Further research is warranted for long-term therapeutic strategies.

Area of Science:

  • Cardiology
  • Cardiovascular Physiology

Background:

  • Ischaemic cardiac dysfunction, characterized by reduced ejection fraction (EF) <40% in stable coronary disease (SCD) patients, presents a significant clinical challenge.
  • Current therapeutic strategies for chronic ischaemic heart disease often have limitations.

Purpose of the Study:

  • To evaluate the effects of glucose-insulin-potassium (GIK) infusion on cardiac function in patients with stable coronary disease and impaired ejection fraction.
  • To assess changes in systolic and diastolic function, haemodynamics, and myocardial perfusion.

Main Methods:

  • Thirty male patients with SCD and EF <40% received a 24-hour infusion of GIK (30% glucose, 300 insulin units, 6 g/l KCl at 1 ml/kg/hr).
  • Measurements included echocardiography, right ventricular catheterisation, and myocardial scintigraphy (99mTc sestamibi) before and after GIK infusion.

Main Results:

  • A significant increase in ejection fraction (EF) from 32.1% to 43.3% (p <0.01) was observed.
  • Diastolic filling periods significantly prolonged (365 to 428 msec, p <0.05), and pulmonary capillary wedge pressure decreased significantly (22.2 to 17.1 mmHg, p <0.01).
  • A non-significant decrease in stress score was noted (13 to 11, p >0.05).

Conclusions:

  • GIK infusion demonstrates potential to improve both systolic and diastolic cardiac function in patients with SCD and reduced EF.
  • These findings suggest GIK may be a viable therapeutic option, but long-term studies are required to confirm its efficacy in chronic ischaemic heart disease management.
Abstract

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...